Statement of Principles concerning toxic vestibulopathy (Reasonable Hypothesis) (No. 88 of 2020)

The instrument defines toxic vestibulopathy in subsection 6(2) as damage to the vestibular organs of the inner ear or the vestibular nerve resulting from exposure to a chemical agent, causing symptoms or signs of vestibular loss. It expressly excludes impairment of balance due to damage to the brain or brainstem. Typical symptoms listed in the note include nausea, vomiting, vertigo, dizziness, disequilibrium, nystagmus (eye jerking) and oscillopsia (blurred vision with head movement). Death from toxic vestibulopathy includes death from a terminal event contributed to by the condition, with “terminal event” defined in the dictionary as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function.

The central legal concept is the “reasonable hypothesis.” This is the evidentiary standard set by sections 120(1) and 120A of the VEA, and by section 338 of the MRCA. The hypothesis must be more than a possibility; it must be reasonable, grounded in sound medical-scientific evidence, and not contrary to the proved facts. The instrument’s factors are the minimum required to raise such a hypothesis. They are not exhaustive proofs; if a factor exists, the hypothesis may be raised unless there is contrary proof that destroys its reasonableness.

The factors in section 8 are grouped into two sets: those relating to clinical onset (factors 1-4 and 9) and those relating to clinical worsening (factors 5-9). The worsening factors apply only to material contribution to or aggravation of a condition suffered or contracted before or during (but not arising out of) relevant service, per subsection 9(2). The factors cover four exposure pathways: (a) taking a drug from the “specified list of drugs” within 30 days before onset or worsening; (b) taking a drug where there is an individual association with development within 30 days of commencing therapy and improvement within three months of cessation; (c) having inner ear exposure to a chemical agent from the “specified list of chemical agents” within 30 days before onset or worsening (requiring a defect in the tympanic membrane); (d) inhaling fumes from jet fuel or having cutaneous contact with jet fuel for a cumulative 2000 hours before onset or worsening, with onset occurring within one year of cessation if exposure ceased; and (e) inability to obtain appropriate clinical management for the condition.

The dictionary specifies two key lists. The “specified list of chemical agents” is narrow: aminoglycoside-containing ear drops, Burow’s solution (5% aluminium subacetate), or surgical antiseptics. The “specified list of drugs” contains 16 categories ranging from amiodarone and aminoglycosides through to vincristine, including immune checkpoint inhibitors, loop diuretics, mefloquine, NSAIDs, opioids, platinum-based chemotherapy, and quinine. “Fumes” is defined as combustion products, aerosols, vapours or dust arising from industrial processes or workplace practices involving refining, manufacture or use of the stated material.

The instrument directly affects veterans and members of the Australian Defence Force who have rendered “relevant service” and who suffer from toxic vestibulopathy, or whose death was contributed to by that condition. Relevant service under the VEA includes operational service, peacekeeping service, hazardous service, and British nuclear test defence service. Under the MRCA, it includes warlike service and non-warlike service. This means that the instrument covers a wide range of current and former service personnel, including those who served in combat zones, peacekeeping missions, training exercises, and nuclear test sites. It also applies to their dependents who claim death benefits.

The instrument will most often affect personnel with histories of exposure to the specified drugs or chemical agents. For example, service personnel who took mefloquine for malaria prophylaxis during deployments in malarious regions are within its scope if they develop vestibular symptoms within 30 days of commencing the drug. Similarly, ground crew who fuelled aircraft over many years - reaching 2000 cumulative hours of jet fuel exposure - may raise a hypothesis if their symptoms appear within one year after cessation of that exposure. Personnel who used aminoglycoside ear drops for chronic ear infections and had a perforated tympanic membrane are also caught.

The instrument also affects those involved in the claims determination process: delegates of the Repatriation Commission, the Veterans’ Review Board, the Administrative Appeals Tribunal, and the Federal Court. They must apply the factors mechanically when assessing whether a reasonable hypothesis exists. Medical practitioners who assess veterans for compensation purposes must be aware of the specific definitions and timeframes, particularly the need to document the exact date of clinical onset and the timing of drug commencement or cessation. Defence Force medical records and personnel files become crucial evidence for proving cumulative jet fuel exposure (often recorded in hours of duty), tympanic membrane integrity, and prescriptions.

The instrument imposes significant evidentiary burdens on claimants. For jet fuel exposure, proving 2000 cumulative hours may be difficult for those with fragmented service history or poor record-keeping. For drug-associated factors, the requirement that improvement occurs within three months of cessation or tapering may exclude those who recover more slowly or who never cease the drug. The narrow list of chemical agents for inner ear exposure (only three types) may leave out other ototoxic chemicals used in military settings, forcing claimants to rely on the drug list or jet fuel pathway. This creates a compliance cost that falls disproportionately on claimants with less documented exposure histories.

The instrument does not create direct duties on private individuals. However, it establishes duties on decision-makers within the veterans’ compensation system. The Repatriation Commission, the Veterans’ Review Board, and reviewing courts must, when applying the reasonable hypothesis standard, treat the existence of any factor in section 8 as sufficient to raise a reasonable hypothesis connecting toxic vestibulopathy to relevant service, subject to any contrary evidence that could displace the hypothesis. They have a duty to assess each factor rigorously: if a claimant establishes a factor, the decision-maker must then consider whether the factor is related to relevant service under section 9. That section requires the factor to have occurred as a result of, or be contributed to by, the person’s service. It is not enough to show exposure during service; the exposure must be due to service. For example, jet fuel exposure that occurred on a civilian job before enlistment cannot be used for a service-related claim unless the service itself involved further jet fuel exposure that contributed.

Claimants have the right to raise a hypothesis based on any of the factors. They are not limited to proving the strongest pathway; the instrument allows multiple factors to be argued concurrently. They also have the right to rely on the dictionary definitions, which are binding. The right to claim aggravation under subsections 8(5)-(9) exists only where the condition was suffered or contracted before or during (but did not arise out of) service. This means that if the condition first appeared after service and was not related to service at onset, the aggravation factors cannot apply; the onset factors must be used instead.

A subtle duty arises from factor 9: “inability to obtain appropriate clinical management for toxic vestibulopathy.” This factor recognises that inadequate treatment can aggravate or worsen the condition. Claimants may need to show that they sought or required clinical management but could not obtain it due to circumstances of service, such as remote deployment, limited medical facilities, or post-discharge barriers. The instrument does not define “appropriate clinical management” or “inability,” leaving room for administrative interpretation. This creates uncertainty: decision-makers may differ on what constitutes appropriate care, and the burden is on the claimant to show a causal link between lack of management and worsening.

Health professionals who treat veterans have no direct duty under the instrument, but their clinical records and opinions will be scrutinised. The instrument effectively creates an evidentiary framework that privileges certain types of medical evidence - notably, clear timelines of drug initiation and cessation, cumulative hour logs for jet fuel, and otological assessments confirming tympanic membrane integrity. Claimants have the practical duty to gather such evidence, which may require costly specialist reports.

This instrument is not a penal instrument. It does not create offences or impose fines or imprisonment. Its enforcement mechanism is the claims process under the VEA and MRCA. If a decision-maker incorrectly applies the factors, the claimant may seek review by the Veterans’ Review Board, then the Administrative Appeals Tribunal, then the Federal Court. The instrument can be judicially reviewed under the Administrative Decisions (Judicial Review) Act 1977 or the Constitution for legal error, such as misinterpreting a defined term or failing to consider a relevant factor.

While there are no direct penalties for non-compliance with the instrument itself, the broader legal framework contains penalties for fraud. A claimant who knowingly makes a false statement in support of a claim - for example, falsely claiming 2000 hours of jet fuel exposure - may be prosecuted under section 135.1 of the Criminal Code (Cth) for obtaining a financial advantage by deception, or under section 56 of the VEA for making a false statement. Penalties can include imprisonment. Similarly, a medical practitioner who provides a false certificate to assist a claim could face professional misconduct proceedings and criminal charges. However, these penalties arise from general law, not from the Statement of Principles.

The instrument’s practical enforcement occurs through the scrutiny applied by DVA delegates and review bodies. If a factor is not properly established, the claim is refused. The Authority itself has no enforcement role after the instrument is made. The instrument does not require any reporting, lodgement, or record-keeping by private entities. It imposes an interpretive burden on decision-makers rather than a regulatory one. The primary cost of enforcement is the administrative cost of assessing claims, which is borne by the taxpayer through DVA’s budget. Claimants who fail to meet the factors may be denied entitlements worth many thousands of dollars per year, which represents a significant personal cost.

The instrument operates within a hierarchy of legislation. It is made under subsection 196B(2) of the VEA, which confers power on the Repatriation Medical Authority to determine Statements of Principles for the purposes of the reasonable hypothesis standard. The instrument itself does not amend or repeal any Act; it is a legislative instrument subject to disallowance by Parliament under the Legislation Act 2003. It must be read together with the VEA and the MRCA as the parent statutes. Specifically, sections 120 and 120A of the VEA and section 338 of the MRCA provide the context: those sections set the standard of proof (reasonable hypothesis) and mandate that a Statement of Principles must be applied when one exists.

Section 10 of the instrument addresses interaction with other Statements of Principles. If a factor in section 8 refers to an injury or disease covered by another Statement of Principles, the factors in that other Statement apply in accordance with its terms as in force from time to time. This is a dynamic cross-reference. For example, if factor 1 refers to “taking a drug from the specified list of drugs” and a person took aminoglycosides that caused renal toxicity, and the renal toxicity is covered by a separate Statement of Principles, then the factors for that renal condition also apply. This prevents claimants from being disadvantaged by a chain-causation argument: the drug-related vestibular condition can be linked to service if the drug itself was taken for a service-related condition, but only if the medical evidence in the other Statement is satisfied.

The instrument also interacts with state and territory workers’ compensation laws in cases where a veteran is also a civilian employee. However, the VEA and MRCA generally provide exclusive compensation for defence service, so such interaction is rare. The instrument does not displace or modify the Safety, Rehabilitation and Compensation Act 1988 (Cth) for civilian employees; it is limited to the military context.

There are potential conflicts with the Therapeutic Goods Act 1989 definitions: the instrument uses “drug” broadly and includes substances like NSAIDs and loop diuretics that are available over the counter, without distinguishing prescription strength. This may lead to disputes about whether NSAID use documented in a service record counts as “taking a drug” even if the record does not specify the brand or dosage. Similarly, “jet fuel” is not defined; if the service member was exposed to aviation gasoline (avgas) rather than Jet A1 or JP-8, the factor may not apply unless the fumes definition covers it. The instrument does not define “jet fuel,” so decision-makers may rely on common usage or DVA policy guidelines, which introduces inconsistency.

The instrument is a new determination made on 30 October 2020, with effect from 30 November 2020. The text does not disclose whether it replaces an earlier Statement of Principles concerning toxic vestibulopathy. However, Statements of Principles are typically revised every few years as medical evidence evolves. If a prior instrument existed, it would have been revoked by this one. The instrument bears the number 88 of 2020, indicating it was one of many SoPs determined that year. No amending instruments are referenced within the text. The Authority has not, as at the date of this instrument, issued any amending determinations; any later amendment would be a separate instrument with its own number and commencement date.

The instrument is unlikely to be amended frequently. The Authority typically issues new instruments when there is a significant development in medical-scientific evidence. Until then, this instrument remains in force. Readers should check the Federal Register of Legislation for any later amending instruments, as the Authority often updates SoPs in batches. The absence of amendment history in the source does not mean amendment history does not exist; it simply was not provided. For practical purposes, users should treat this instrument as the current law for claims made on or after 30 November 2020, subject to any subsequent revocations or determinations.

The source text provides no information on litigation history. The instrument itself is relatively recent (2020), and reported decisions of the AAT or Federal Court that apply it may not be numerous. However, Statements of Principles of this type are frequently litigated. Common issues include: the date of clinical onset (whether the condition started after the exposure window); the meaning of “cumulative period of at least 2,000 hours” (can it include part-time exposure over many years?); whether “inability to obtain appropriate clinical management” requires a finding that management was unavailable, ineffective, or refused; and disputes over whether a drug is on the specified list (particularly “immune checkpoint inhibitors” as a category). Claimants have also argued that the requirement for tympanic membrane defect for inner ear exposure is unduly restrictive where the chemical agent caused the perforation itself.

Because the source does not cite any cases, no case names can be given. The absence of litigation in the source does not mean the instrument is unchallenged. It is likely that the Administrative Appeals Tribunal has dealt with a number of cases applying this SoP. Any competent legal professional would run a search on AustLII or Westlaw for decisions citing “No. 88 of 2020” or “toxic vestibulopathy” in conjunction with “Veterans’ Entitlements Act 1986” to understand how the factors have been interpreted in practice. The deep dive reader must be aware that the static text of the instrument does not capture the gloss placed on it by tribunals, and the litigation history is dynamic.

Several features of the instrument are likely to catch out unrepresented claimants or poorly prepared advocates.

First, the inner ear exposure pathway (factors 3 and 7) requires a defect in the tympanic membrane - that is, a perforated eardrum. If the chemical agent was applied to an intact eardrum, the factor is not available. Claimants with a history of aminoglycoside ear drops for otitis externa (outer ear infection) without a documented perforation cannot use this pathway. They must instead rely on systemic drug exposure (factors 1 or 2) if the drug was also taken orally or intravenously.

Second, the jet fuel exposure pathway (factors 4 and 8) demands a cumulative 2000 hours of inhalation or cutaneous contact. This is a high threshold. For context, a full-time worker handling jet fuel for 40 hours per week, 48 weeks per year, would need just over one year to reach 2000 hours. But many service members are exposed intermittently, and record keeping is often poor. Moreover, if exposure ceased, the clinical onset must occur within one year of that cessation. This can be particularly harsh for those who develop symptoms decades later; the instrument effectively presumes a latency no longer than one year, which may be medically unrealistic for some ototoxic substances but is binding for the hypothesis.

Third, the drug associated factors (2 and 6) impose a bidirectional test: the symptoms must develop within 30 days of starting the drug AND must decrease within three months of stopping or reducing it. This is difficult to meet for drugs that are often taken long term (e.g., mefloquine given weekly for months) or where the symptoms do not resolve quickly. If a claimant continues the drug long after symptoms appear, the improvement condition cannot be satisfied unless they later taper off.

Fourth, the “specified list of chemical agents” is very narrow: only aminoglycoside-containing ear drops, Burow’s solution, or surgical antiseptics. This excludes many industrial solvents, heavy metals, or carbon monoxide that can cause vestibular damage. The Authority has elected to list only those three, perhaps because the evidence linking them to vestibular damage is strongest. Claimants exposed to other chemicals must try the drug list or jet fuel factor, or pursue a claim outside the SoP framework (which is difficult given the requirement to apply SoPs).

Fifth, the “inability to obtain appropriate clinical management” factor is undefined. It does not specify what constitutes inappropriateness. Could a claimant argue that a doctor refused to prescribe vestibular suppressants? Or that a physiotherapy programme was unavailable on base? The scope of this factor is likely to be contentious.

Sixth, subsection 9(2) limits the worsening factors (5-9) to cases where the condition was contracted before or during service but did not arise out of service. If the condition arose out of service (i.e., was already service-related), then the worsening factors do not apply; instead, the onset factors and the provisions on aggravation of a service-related condition under the VEA would govern. This can lead to circular arguments about causation.

Compliance with this instrument is relevant to two groups: claimants and decision-makers. For a claimant, the first step is to obtain a medical diagnosis of toxic vestibulopathy as defined. The diagnosis must confirm damage to the vestibular organs or nerve from a chemical agent, and exclude balance impairment due to brain or brainstem damage. A specialist otologist or neurologist should provide this. The claimant must then identify which factor or factors in section 8 potentially apply and gather supporting evidence.

For drug-related factors (1, 2, 5, 6), the claimant needs records of prescription, administration, over-the-counter purchase, or medical notes showing the exact dates the drug was taken. The “specified list of drugs” is broad but each drug must be matched to the timing requirement: within 30 days before clinical onset or worsening. For factor 2 (or 6), the claimant also needs evidence that symptoms improved within three months of cessation or tapering. This may require serial symptom diaries or follow-up medical assessments. If the claimant continued the drug for a longer period, that evidence may weaken the case.

For jet fuel exposure (factors 4, 8), the claimant needs documentation of cumulative 2000 hours of inhaling fumes or cutaneous contact. This can include service records showing hours worked as a jet fuel handler, aircraft refueller, or mechanic working near engines. If records are incomplete, affidavits from colleagues or supervisors may help, but the decision-maker is entitled to place less weight on uncorroborated statements. The claimant must also show that exposure ceased at some point and that onset occurred within one year thereafter. If the claimant was still exposed at the time of onset, the one-year cessation requirement does not apply (but the factor requires cessation before onset for the timing clause to operate). That is, factor 4(b) says “where that exposure has ceased, the clinical onset … has occurred within one year of cessation.” If exposure has not ceased at the time of onset, the subparagraph does not apply, and arguably the factor cannot be proven - a potential drafting trap.

For inner ear exposure (factors 3, 7), the claimant needs medical evidence of a tympanic membrane defect (perforation) at the time of exposure, and evidence that the chemical agent listed (aminoglycoside ear drops, Burow’s solution, or surgical antiseptics) was applied to the ear. Audiometry and otoscopy reports are essential.

For factor 9 (inability to obtain appropriate clinical management), the claimant must show that they required specific treatment for toxic vestibulopathy (such as vestibular rehabilitation, medication, or surgery) and that they were unable to obtain it due to service-related circumstances - for example, being posted to a remote location without an ENT specialist, or being denied treatment by a military doctor.

Decision-makers must check each element of the claimed factor against the dictionary definitions. They should not accept a factor if the definitions are not met - for example, if the chemical agent is not listed, even if it is ototoxic. They must also assess whether the factor is related to relevant service under section 9, which requires a causal or contributory link. Practical compliance for decision-makers means having a checklist derived from the instrument and ensuring that all notes and timeframes are verified. The instrument is a legally binding rule of evidence; it should be followed capably and consistently.